Newsroom | 25795 results

VANCOUVER, British Columbia--(BUSINESS WIRE)--Kardium Inc., a private medical device company that’s advancing the way the world treats atrial fibrillation (AF), announced late-breaking, one-year clinical trial results for its innovative pulsed field ablation (PFA) device—the Globe PF System. These pivotal findings from the PULSAR IDE study were announced at the Heart Rhythm Society (HRS) meeting in San Diego1, highlighting the safety and efficacy data of the Globe PF System, which is currently...

BETHESDA, Md. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data at the World Vaccine Congress 2025 on LHNVD-303, the company's composite peptide vaccine for sepsis due to bacterial infections and its applications in inflammatory diseases. The World Vaccine Congress took place in Washington, D.C. from April 22-24. Sepsis is a life-threatening com...

MUNICH--(BUSINESS WIRE)--CatalYm today announced the presentation of the first preclinical data demonstrating that the company’s clinical-stage antibody visugromab can improve the anti-tumor activity of antibody-drug conjugates (ADCs). The data will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in Chicago, IL, April 25-30, 2025. The poster will highlight the potential of targeting Growth Differentiation Factor 15 (GDF-15) to enhance the activit...

SEATTLE--(BUSINESS WIRE)--Talus Bioscience, a technology-enabled therapeutics company, today announced new preclinical data from programs targeting transcription factors in chordoma, non-small cell lung cancer, and advanced prostate cancer. The data, presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, held April 25-30, support Talus Bio’s first-in-class approach to target previously undruggable transcription factors using regulome-scale discovery in live human...

SAN DIEGO--(BUSINESS WIRE)--Onchilles Pharma Presents New Data at AACR 2025 Highlighting N17350, a Next-Generation Cytotoxic Therapeutic Leveraging the ELANE Pathway...

DURHAM, N.C. & MÄNNEDORF, Switzerland--(BUSINESS WIRE)--BioSkryb Genomics and Tecan Group (SIX Swiss Exchange: TECN), today introduced a high-throughput single-cell workflow, combining BioSkryb’s 384-well format of the ResolveOME™ Whole Genome and Transcriptome Single-Cell Core Kit with the Uno Single Cell Dispenser™, provided by Tecan. The integrated solution enables parallel high-resolution analysis of hundreds to thousands of individual cells, addressing growing demand for scalable, multiomi...

COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the leading commercial quantum computing and networking company, today announced the joint development of a new quantum innovation center with EPB of Chattanooga, a leading energy and communications company. This strategic partnership will further establish Chattanooga as the catalyst in Tennessee's emergence as the national hub for quantum innovation. The EPB Quantum Center will house a state-of-the art IonQ Forte Enterprise quantum comput...

SAN FRANCISCO--(BUSINESS WIRE)--Kiddom offers materials customized for the 2025 Tennessee Academic Standards for Science...

MCLEAN, Va. & MENLO PARK, Calif.--(BUSINESS WIRE)--Booz Allen Hamilton (NYSE: BAH) and Meta today announced the development and successful demonstration of a novel AI-powered tech stack, accelerated by NVIDIA CUDA GPUs, to support critical work on the International Space Station (ISS) National Lab. This effort is believed to be the first of its kind, setting the stage for space exploration and operations across a variety of disconnected environments. The goal in building the tech stack – dubbed...

フィラデルフィア--(BUSINESS WIRE)--（ビジネスワイヤ） -- 革新的なバイオ医薬品治療に特化した世界有数の開発・製造受託機関（CDMO）のPCIファーマ・サービシズ（「PCI」）は、日本の味の素株式会社の100%子会社で米国を拠点とする無菌充填製剤CDMO、味の素アルテア株式会社（アルテア）の全株式を取得します。2025年5月に完了する予定のこの買収により、PCIはプレフィルドシリンジとカートリッジ（これらのフォーマット用のアイソレーター技術を含む）ならびに抗体薬物複合体（ADC）に適した高活性製剤の北米初の製造拠点となります。 アルテアの注射用医薬品における臨床段階から商業化までの堅牢なサービスは、PCIの豊富な業界経験をさらに強化し、同社のグローバルな無菌充填仕上げ能力および高度な薬物送達技術における確かな専門知識を支えるものとなります。また、アルテアの拡張可能なカスタムオリゴヌクレオチドおよびペプチドに関する豊富な知識基盤、スキルセット、および製造能力は、PCIの複雑な製剤および凍結乾燥技術における既存の製造能力を補完し、ナノ粒子、mRNA、MABs、タンパク...